Citadel Advisors
ADAP

Citadel Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Citadel Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-143,500
Closed -$18.7K – 12523
2025
Q3 		$18.7K Buy
+143,500
New +$19.7K ﹤0.01% 12499
2025
Q2 		– Sell
-14,200
Closed -$2.8K – 12334
2025
Q1 		$2.8K Sell
14,200
-2,100
-13% -$1.09K ﹤0.01% 14009
2024
Q4 		$8.78K Buy
16,300
+10,500
+181% +$7.65K ﹤0.01% 13673
2024
Q3 		$5.51K Sell
5,800
-7,600
-57% -$8.62K ﹤0.01% 13480
2024
Q2 		$13.1K Sell
13,400
-15,100
-53% -$16.6K ﹤0.01% 12959
2024
Q1 		$45K Buy
+28,500
New +$34.4K ﹤0.01% 12266
2023
Q3 		– Sell
-2,500
Closed -$2.31K – 14211
2023
Q2 		$2.31K Hold
2,500
– – ﹤0.01% 13800
2023
Q1 		$2.73K Sell
2,500
-100
-4% -$155 ﹤0.01% 14113
2022
Q4 		$3.8K Buy
+2,600
New +$4.21K ﹤0.01% 14170
2022
Q2 		– Sell
-14,800
Closed -$30K – 12773
2022
Q1 		$30K Buy
+14,800
New +$39.9K ﹤0.01% 13097
2021
Q4 		– Sell
-16,100
Closed -$83K – 13702
2021
Q3 		$83K Buy
16,100
+1,000
+7% +$4.49K ﹤0.01% 13039
2021
Q2 		$64K Sell
15,100
-2,300
-13% -$11.2K ﹤0.01% 13214
2021
Q1 		$92K Buy
+17,400
New +$99.6K ﹤0.01% 12534
2020
Q4 		– Sell
-81,100
Closed -$647K – 10850
2020
Q3 		$647K Sell
81,100
-134,000
-62% -$1.17M ﹤0.01% 6826
2020
Q2 		$2.15M Buy
215,100
+188,500
+709% +$1.18M ﹤0.01% 4440
2020
Q1 		$72K Buy
+26,600
New +$88.3K ﹤0.01% 8838
2018
Q4 		– Sell
-14,000
Closed -$190K – 9015
2018
Q3 		$190K Buy
+14,000
New +$147K ﹤0.01% 8245

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citadel Advisors's ADAP Position: Q1 2025 in Review

Citadel Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 175,052 shares — an estimated $90.6K sold.

Citadel Advisors first reported a position in ADAP in Q2 2015 and held it in 29 quarters. The position peaked at $39M in Q3 2020. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Citadel Advisors reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 175,052 Adaptimmune Therapeutics shares in Q1 2025, an estimated $90.6K.
  • Citadel Advisors first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 29 quarters.
  • Citadel Advisors's Adaptimmune Therapeutics position peaked at $39M in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.